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a b s t r a c t
GeneOntology (GO)provides a controlled vocabulary todescribe the attributes of genes andgeneproducts
in any organism. Although onemight initiallywonderwhat relevance a ‘controlled vocabulary’might have
for cardiovascular science, such a resource is proving highly useful for researchers investigating complex
cardiovascular disease phenotypes aswell as those interpreting results fromhigh-throughputmethodolo-
gies. GO enables the current functional knowledge of individual genes to be used to annotate genomic or
proteomic datasets. In this way, the GO data provides a very effective way of linking biological knowledge
with the analysis of the large datasets of post-genomics research. Consequently, users of high-throughput
methodologies such as expression arrays or proteomics will be the main beneﬁciaries of such annotation
sets. However, as GO annotations increase in quality and quantity, groups using small-scale approachesigh-throughput analysis
hromosome 9
will gradually begin to beneﬁt too. For example, genomewide association scans for coronary heart disease
are identifying novel genes, with previously unknown connections to cardiovascular processes, and the
comprehensive annotation of these novel genes might provide clues to their cardiovascular link. At least
4000 genes, to date, have been implicated in cardiovascular processes and an initiative is underway to
focus on annotating these genes for the beneﬁt of the cardiovascular community. In this article we review
the current uses of Gene Ontology annotation to highlight why Gene Ontology should be of interest to all
those involved in cardiovascular research.
© 2008 Elsevier Ireland Ltd.
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rocesses and disease, with thousands of publications each year
dding to our accumulated knowledge of these systems. How-
ver, genome-sequencing projects have led to the identiﬁcation of
housands of genes in higher vertebrates, the majority of which
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are only characterised by their sequence and genomic location,
with their potential involvement in cardiovascular systems await-
ing experimental investigation. High-throughput methodologies,
such as expression arrays or proteomics are providing substantial
information about the properties of these newly identiﬁed genes,
through the detailed characterisation of themolecular composition
of entire tissues, cells or organelles at both speciﬁc developmental
and speciﬁc disease states or through protein binding or cel-4.1. Request for community participation . . . . . . . . . . . . . . . . . . . . . . . . . . .
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1. Introduction
Until recently, the study of speciﬁc pathways or individual
molecules has been themajor approach to understanding the intri-
cate molecular and cellular details associated with cardiovascularlular location studies. Consequently, such investigations provide
researchers with the potential to rapidly increase our understand-
ing of complex interactions and biological functions within the
cardiovascular system. However integrating such high-throughput
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he function of individual genes is an essential step that is neces-
ary to ensure that all experimental approachesmake an impact on
urrent research projects. Fortunately, the Gene Ontology Consor-
ium (GOC) has been developing terms to describe the functional
ttributes of gene products, across all species, in a consistent
nd computer-friendly manner to enable the integration of all
f these data. This system of terms, called Gene Ontology (GO),
nables the accumulated knowledge about individual gene prod-
cts and their functional domains to be included in individual
ene records, in biological sequence databases, and within high-
hroughput analysis software. This information can then be applied
y high-throughput analysis software to aid in the interpretation
f large datasets. By providing current functional knowledge in a
ormat that can be exploited by high-throughput technologies, the
OC provides a major freely available public annotation resource
hat can help bridge the gap between data collation and data anal-
sis [1] (www.geneontology.org).
The success of GO rests on the philosophy behind it; GO
as designed by biologists to improve data integration and con-
equently enables genes to be classiﬁed and grouped together
ccording to their functional properties [2–4]. At times the English
anguage can be rather vague, with the majority of words having
variety of subtly different meanings. Similarly, scientiﬁc terms
r phrases can have dual meanings. Consequently, one of the pri-
ary aims of GO is to create a single, explicit deﬁnition for each
iological term so that these terms can be applied and interpreted
onsistently by all biologists. All such terms are provided as three
tructured vocabularies of terms (ontologies) that describe the
olecular functions that gene products normally carry out, the bio-
ogical processes that gene products are involved in and lastly the
ubcellular locations (cellular components) where gene products are
ctive. For example, the annotations for cholesteryl ester transfer
rotein (CETP) include the Molecular Function term: ‘cholesterol
ransporter activity’, the Biological Process term: ‘reverse choles-
erol transport’ and the Cellular Component term: ‘high-density
ipoprotein particle’; whereas the annotations for troponin C type 1
TNNC1) include the Molecular Function term: ‘troponin I binding’,
he Biological Process term: ‘regulation of muscle contraction’ and
he Cellular Component term: ‘troponin complex’.
The terms in GO are structured as directed acyclic graphs,where
ach term can have multiple relationships to broader ‘parent’ and
ore speciﬁc ‘child’ terms (Fig. 1). This hierarchical structure pro-
uces a representation of biology that allows a greater amount of
exibility in data analysis thanwould be afforded by a format based
n a simple list of terms. Users can manipulate the structure to
ee either a broad overview of the general functional attributes
resented by a set of data, or focus in on speciﬁc sections in the
ntology to investigate in greater detail.
The second resource supplied by the GOC are datasets of GO
erms associated with the appropriate genes and their products,
hus providing a resource of diverse detailed functional annotation
or many different species [1] (www.geneontology.org/GO.current.
nnotations.shtml). These annotations are created by 13 differ-
nt annotation groups, including Gene Ontology Annotation @ EBI
GOA), FlyBase, and theMouseGenomeDatabase.Dependingon the
mount of published data available, gene/protein identiﬁers can be
nnotated with multiple GO terms from any, or all, of the three
ene ontologies (Fig. 1). Annotations can be produced either by a
urator reading published scientiﬁc papers and manually creating
ach association or by a software engineer applying computational
echniques topredict associations [5]. These twobroadcategoriesof
echniques have their own advantages and disadvantages, but both
equire skilledbiologists and softwareengineers toensure that con-
ervative, high-quality annotations are created. The annotation of
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or a highly studied gene like TNF could take several days (Fig. 2)
r, for a more recently described gene like CDKN2B, may only take
few hours (Fig. 1).
. Use of GO in high-throughput studies
As the number of high-throughput methodologies has
ncreased, so has the number of ways in which GO annota-
ion data has been exploited to link experimental results to current
unctional knowledge.
Proteomes and differentially regulated mRNAs can be analysed
ith GO data to provide an overview of the predominant activities
he constituent proteins are involved in or where they are nor-
ally located. For example Ashley et al. [6] used GO to compare
he genes up-regulated in de novo atherosclerosis with those asso-
iated with in-stent restenosis. They found a signiﬁcant proportion
f genes up-regulated following de novo atherosclerosis were asso-
iated with inﬂammatory processes, whereas a high proportion of
n-stent restenosis up-regulated genes had GO terms indicating an
nvolvementwith cell growthandassociationwith theextracellular
atrix [6].
Often the generation of hypotheses to explain proteome-wide
lterations in response to certain diseases, such as cardiac hyper-
rophy [7], or stress states, such as hypoxia [8], rely on the use of
O annotation data. In such studies an indication of underlying
ellular mechanisms that may account for an observed pheno-
ype can be obtained using GO to cluster subsets of proteins that
hare related GO annotation, and found to be similarly over- or
nder-expressed in the disease or stress state. For example, Pan et
l. [7] found over-expressed cardiac microsomal membrane pro-
eins in mouse hyper- or hypocontractile hearts were enriched
ith GO terms describing fat and carbohydrate metabolism and
-protein-dependent signalling pathways [7]. Enrichment of these
O terms validated the investigators proteomic method and was
onsistent with the suggestion that the deregulation of calcium-
ependent cardiac contractility resulted in compensatory growth
ctivities.
Theability to reviewexperimental resultswith respect toknown
unctional information has also proved useful when investigators
eed to select a subset of proteins to analyse in greater depth in
rder to identify new sets of biomarkers for a certain disease. This
pproachhas enabled investigators of buccal carcinoma [9], Parkin-
on disease [10] and chronic kidney disease [11] to identify new
iomarkers for these diseases. Furthermore, in all of these reports
he enriched GO categories indicated disease-associated deregu-
ated processes.
GO can also be used to provide a link between the protein bind-
ng network and the activities/locations of the participant proteins.
se of cellular component GO annotations can aid data visualisa-
ion or conﬁrm whether a particular set of interactions is likely to
ccur in vivo. Dyer et al. [12] used GO data to investigate interac-
ions of human proteins with viral pathogens and found that many
ifferent pathogens target the same processes in the human cell,
uch as regulation of apoptosis, even though they may interact
ith different proteins. Similarly, many studies have focused on
‘guilt-by-association’ hypothesis, where the involvement of pro-
eins in a particular pathway can be hypothesised in relation to
he processes their interacting proteins carry out. To this end GO
nnotations are integrated in the GEOMI [13] and Cytoscape [14]
etwork visualization tools.
A number of proteomic investigations have found that GO data
rovides an indispensable resource to indicate the success of a
articular subcellular enrichment strategy or large scale confocal
icroscopy analyses [15–18]. Kislinger et al. [15] used GO data to
erify that their subcellular fractionation protocol efﬁciently iso-
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Fig. 1. Protein record page of the QuickGO browser, showing all annotations for the human CDKN2B protein (www.ebi.ac.uk/ego/GProtein?ac=P42772). The QuickGO protein
recordpagedisplays a short summary for the chosenUniProtKBprotein accessionnumber, togetherwith associatedGOannotations.Descriptions about the information in each
column are provided in green call-outs, red arrows and circles show some of the additional information hyperlinked to this protein record. In the QuickGO GO term ancestor
chart the term ‘cytoplasm’ is shown to be a child of the broader parent term intracellular part. The GO term ‘cytoplasm’ was associated with the CDKN2B record based on the
direct assay ‘immunoﬂuorescent staining’ and given the evidence code ‘IDA’, an acronym for ‘inferred from direct assay’ (text in the abstract highlighted yellow). 17 different
evidence codes can be used to categorise the type of evidence available to support the annotation, one ofwhich (IEA) is use to indicate an ‘electronic’ source for the annotation,
t tion a
f ion Tu









bhe remaining 16 are all used for manually curated annotations. For further informa
or an explanation about how some of these annotations are made, see the Annotat
he references to color in this ﬁgure legend, the reader is referred to the web versio
ated subcellular compartments. For example, of the nearly 600
roteins detected exclusively in the nuclear fractions, nearly half
ereeither annotated solely to thenucleusorhada functionknown
o be localized within the nucleus (e.g. transcription factors [15]).
arbe et al. [18] applied GO annotation to validate the protein sub-
ellular locations identiﬁed using protein-speciﬁc antibodies and




obout the use of evidence codes see www.geneontology.org/GO.evidence.shtml and
torial at EBI (www.ebi.ac.uk/GOA/annotationexample.html). (For interpretation of
e article.)
ubcellular locations identiﬁed in human cell lines were supported
y existing GO annotation data [18].
Despite thewidevariety of applications thatGO is used for, there
re many aspects to biological processes that are not addressed by
his database. In particular, GO only describes the normal, physio-
ogical function of a protein, rather than the pathological function
f a protein in a diseased situation. Furthermore, the dynamic rela-
12 R.C. Lovering et al. / Atherosclerosis 205 (2009) 9–14
Fig. 2. Protein record page of the QuickGO browser, showing the manual annotations for the human TNF protein (www.ebi.ac.uk/ego/GProtein?ac=P01375). TNF is described
in over 55,000 publications, however the annotations currently associated with human TNF have been extracted from only 15 of these publications. A review of these
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ionships between protein function, its cellular location (including
ts intracellular location, cell speciﬁcity and developmental spe-
iﬁc expression) and how this relationship inﬂuences the biological
rocesses a protein is involved in are not currently represented by
O. Protein interaction databases such as BioGrid [19], Biomolec-
lar Interaction Network Database [20], Human Protein Reference
atabase [21] and IntAct [22] enable complex protein interaction
etworks to be investigated. However, at present there is no sin-
le database that enables complex biological relationships to be
nvestigated. The content of GOC database is inﬂuenced by the
uration groups who are submitting data, therefore some groups
f organisms, such as viruses, are not well represented by this
atabase. Details about some of the other available ontologies, such
s cell type or human disease ontologies, are available at the Open
iomedical Ontologies web site (www.obofoundry.org).
. Where to ﬁnd Gene Ontology and GO annotations
A large range of applications have been developed speciﬁcally
or the visualization of GO and its associated annotation data, and
he computational and statistical analysis of large datasets with GO
4,23]. Currently there are 48 tools for gene expression andmicroar-
ay analysis and 20 GO browsers, all of which are listed on the GOC
ools web page (www.geneontology.org/GO.tools.shtml). In addi-
ion to their inclusion indedicatedGObrowsers,GOannotationsare
lso imported into many of the top biological databases, including
niProtKB, Ensembl, EntrezGene and GeneCards.
To enable the scientiﬁc community to effectively use the GO
ocabularies and annotations, a number of web-based tools have
een developed by both members of the GOC and third parties
o search, browse and view the GO hierarchy and annotations
Table 1). Such browsers include AmiGO (amigo.geneontology.
rg/cgi-bin/amigo/go.cgi), QuickGO (www.ebi.ac.uk/ego) and the
GI GO browser (www.informatics.jax.org/searches/GO form.
html). Each of these browsers has its own unique features and
aries slightly in the functionality available to users. All three
f these browsers have a variety of hyperlinks from the protein
ecords to the GO term records and to the appropriate publication
eferences, andAmiGOandQuickGObothprovide a variety of ﬁlter-
ng options tomodify the search query, enabling users to tailor their
ownload set. In AmiGO, the GOC browser, the GO term records
learly show the number of proteins annotated with that term
y all GOC databases, however the protein records only include
anual annotation data. The QuickGO browser, produced by the
OA group at the European Bioinformatics Institute (EBI), provides
simple view of the GO annotation data available, including data
erived from both manual and electronic pipelines. Users can also






seful Gene Ontology links.
ction URL
hoose the right software tool for your dataset [4,23] www
ownload GO annotations www
wiki
ftp:/
ind out about the GO annotation process [3–5] www
rowse GO terms and GO hierarchy amig
iew gene product speciﬁc GO annotations www
amig
nderstand GO evidence codes www
ind out about the Cardiovascular GO Annotation Initiative [24] www
earch the cardiovascular gene list www
uggest improvements to speciﬁc gene annotations wiki
www
uggest improvements to speciﬁc GO terms www
ontact GO curators GOarosis 205 (2009) 9–14 13
dentiﬁers orGO terms, anduseQuickGO tomapbetween sequence
dentiﬁer types (www.ebi.ac.uk/GOA/annotationexample.html).
he MGI database is the primary source of mouse GO annotations,
nd its ‘Gene Ontology Classiﬁcations’ records provide three differ-
nt views of the associated terms, a text summary, a tabulated list
nd a graphical view. Alternatively, for high-throughput analysis
ools entire sets of annotations can be downloaded from the GOC
www.geneontology.org/GO.current.annotations.shtml) or EBI
ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/) and following the
aunch of the Cardiovascular GO Annotation Initiative (www.
ardiovasculargeneontology.com) [24] funded by the British Heart
oundation, a cardiovascular-speciﬁc dataset is now also
vailable as a single download (ftp://ftp.ebi.ac.uk/pub/databases/
O/goa/bhf-ucl/).
Many tools havebeendeveloped to allowusers toperformabulk
uery of GO using a list of gene, protein or probe identiﬁers, that
ave been identiﬁed from proteomics or other high-throughput
xperiments [4,23]. A full list of these tools is available at the GOC
eb site (www.geneontology.org/GO.tools.shtml#micro).
. Manual annotation—the way forwards?
In theory, text-mining software can be used to extract Gene
ntology terms from the scientiﬁc literature and associate these
o individual gene records [25,26]. However, the written style of
cientiﬁc papers represents a substantial obstacle that needs to be
vercome for such ‘automated’ methods to be successful. Papers
re written as interesting text rather than as a list of results and
onclusions. Consequently, a single function for one gene prod-
ct may be discussed using a series of similar yet non-overlapping
escriptions. The result is that although text mining is proving to
e a useful curation aid for locating papers, it is unable to provide
orrect, detailed descriptions of the functions and processes with
hich a gene product is involved [27].
Manual gene annotation is an expensive and time-consuming
lternative, but does ensure high-quality annotation is achieved.
he most accurate, detailed source of functional information for
nnotationwould ideally be provided by scientists working in rele-
ant ﬁelds, rather than by a curatorwhomaybe unfamiliarwith the
peciﬁc details of a set of genes. However, as annotation guidelines
end to be highly detailed, and annotation a highly time-consuming
ctivity for many bench scientists, bringing the research commu-
ity closer to the annotation process is a difﬁcult yet valuable goal
or curation projects [28,29].
The Cardiovascular GO Annotation Initiative is prioritis-
ng the manual annotation of human genes implicated with
ardiovascular processes. In order to do this a list of over
000 cardiovascular-associated genes has been compiled, draw-
.geneontology.org/GO.tools.shtml
.geneontology.org/GO.current.annotations.shtml,









































































[4 R.C. Lovering et al. / Ath
ng on the expertise of several advisors for the project [24]
www.cardiovasculargeneontology.com). A concentrated effort to
mprove the information content provided in themanual GO anno-
ation of genes involved in the cardiovascular system is now
nderway, this will ensure a comprehensive, up-to-date summary
f the current literature for each gene is available [24].
.1. Request for community participation
For the Cardiovascular GO Annotation Initiative to have a
ubstantial impact in this area of biology, it is important that
xperts from the cardiovascular community are consulted to
nsure that the current accumulated knowledge has been com-
rehensively reviewed and correctly summarised by the dedicated
uration team. Consequently a variety of online facilities have
een put in place to encourage scientists to contribute to
his initiative [24] (Table 1). Scientists interested in contribut-
ng can either simply supply the curators with details of key
xperimental publications for curation or can provide more
etailed information or commentary, such as reviewing partic-
lar annotation sets and pointing out any experimental data
hat might be missing, wrong or controversial. This informa-
ion can be sent to GO curators either by direct email to the
O Annotation teams based at UCL, GOannotation@ucl.ac.ukail,
r EBI, goa@ebi.ac.uk, using the online user feedback form
ww.ebi.ac.uk/GOA/contactus.html, or by editingwiki pages set up
or this purpose wiki.geneontology.org/index.php/Cardiovascular.
ubmitted data is regularly reviewed and scientists are notiﬁed
hen their contributions have been incorporated.
. Conclusion
TheCardiovascularGOAnnotation Initiative is currently theonly
O annotation project focused on a speciﬁc ﬁeld of human biology.
he analysis of the large datasets post-genomics research offers the
otential to rapidly advance our understanding of both the basic
nd clinical aspects of atherosclerosis. Hopefully the cardiovascular
ommunity will recognise the potential of this resource, actively
ontribute to it and reap the rewards in the near future!
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